Appraisal of anti-idiotypic antibodies in the treatment of solid tumors in humans

David M Euhus, J. H. Wong

Research output: Contribution to journalArticle

Abstract

Anti-idiotypic antibodies may be valuable in the induction of antitumor immunity in two ways-they can serve as a ready source of antigen when the appropriate TAA is difficult or impossible to purify. More importantly, regulatory anti-idiotypic antibodies can activate specific T-helper cells, bringing all the components of cellular immunity to bear on neoplastic process. Although the results in studies in animals have demonstrated resistance to tumor challenge after immunization with anti-idiotypic antibodies, studies of humans with advanced malignancies have failed to produce substantial clinical results. Nevertheless, immunization with anti- idiotypic antibodies has influenced some tumors. These studies represent important, initial steps toward understanding the immune network and modulating it in favor of the host, against human tumors. As a continued understanding of the immune network evolves and strategies for activating and suppressing specific immune responses are developed, it should be possible to design vaccines for specific uses. Although current anti-idiotypic vaccines do not seem promising for the treatment of established solid tumors in humans, we can look with anticipation to studies of polyvalent vaccines for the prevention of carcinoma in high risk groups.

Original languageEnglish (US)
Pages (from-to)89-96
Number of pages8
JournalSurgery Gynecology and Obstetrics
Volume175
Issue number1
StatePublished - 1992
Externally publishedYes

Fingerprint

Anti-Idiotypic Antibodies
Vaccines
Neoplasms
Immunization
Neoplastic Processes
Therapeutics
Helper-Inducer T-Lymphocytes
Cellular Immunity
Immunity
Carcinoma
Antigens

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Surgery

Cite this

Appraisal of anti-idiotypic antibodies in the treatment of solid tumors in humans. / Euhus, David M; Wong, J. H.

In: Surgery Gynecology and Obstetrics, Vol. 175, No. 1, 1992, p. 89-96.

Research output: Contribution to journalArticle

@article{108a80ee4c3445bcb8b8883f811e791f,
title = "Appraisal of anti-idiotypic antibodies in the treatment of solid tumors in humans",
abstract = "Anti-idiotypic antibodies may be valuable in the induction of antitumor immunity in two ways-they can serve as a ready source of antigen when the appropriate TAA is difficult or impossible to purify. More importantly, regulatory anti-idiotypic antibodies can activate specific T-helper cells, bringing all the components of cellular immunity to bear on neoplastic process. Although the results in studies in animals have demonstrated resistance to tumor challenge after immunization with anti-idiotypic antibodies, studies of humans with advanced malignancies have failed to produce substantial clinical results. Nevertheless, immunization with anti- idiotypic antibodies has influenced some tumors. These studies represent important, initial steps toward understanding the immune network and modulating it in favor of the host, against human tumors. As a continued understanding of the immune network evolves and strategies for activating and suppressing specific immune responses are developed, it should be possible to design vaccines for specific uses. Although current anti-idiotypic vaccines do not seem promising for the treatment of established solid tumors in humans, we can look with anticipation to studies of polyvalent vaccines for the prevention of carcinoma in high risk groups.",
author = "Euhus, {David M} and Wong, {J. H.}",
year = "1992",
language = "English (US)",
volume = "175",
pages = "89--96",
journal = "Journal of the American College of Surgeons",
issn = "1072-7515",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Appraisal of anti-idiotypic antibodies in the treatment of solid tumors in humans

AU - Euhus, David M

AU - Wong, J. H.

PY - 1992

Y1 - 1992

N2 - Anti-idiotypic antibodies may be valuable in the induction of antitumor immunity in two ways-they can serve as a ready source of antigen when the appropriate TAA is difficult or impossible to purify. More importantly, regulatory anti-idiotypic antibodies can activate specific T-helper cells, bringing all the components of cellular immunity to bear on neoplastic process. Although the results in studies in animals have demonstrated resistance to tumor challenge after immunization with anti-idiotypic antibodies, studies of humans with advanced malignancies have failed to produce substantial clinical results. Nevertheless, immunization with anti- idiotypic antibodies has influenced some tumors. These studies represent important, initial steps toward understanding the immune network and modulating it in favor of the host, against human tumors. As a continued understanding of the immune network evolves and strategies for activating and suppressing specific immune responses are developed, it should be possible to design vaccines for specific uses. Although current anti-idiotypic vaccines do not seem promising for the treatment of established solid tumors in humans, we can look with anticipation to studies of polyvalent vaccines for the prevention of carcinoma in high risk groups.

AB - Anti-idiotypic antibodies may be valuable in the induction of antitumor immunity in two ways-they can serve as a ready source of antigen when the appropriate TAA is difficult or impossible to purify. More importantly, regulatory anti-idiotypic antibodies can activate specific T-helper cells, bringing all the components of cellular immunity to bear on neoplastic process. Although the results in studies in animals have demonstrated resistance to tumor challenge after immunization with anti-idiotypic antibodies, studies of humans with advanced malignancies have failed to produce substantial clinical results. Nevertheless, immunization with anti- idiotypic antibodies has influenced some tumors. These studies represent important, initial steps toward understanding the immune network and modulating it in favor of the host, against human tumors. As a continued understanding of the immune network evolves and strategies for activating and suppressing specific immune responses are developed, it should be possible to design vaccines for specific uses. Although current anti-idiotypic vaccines do not seem promising for the treatment of established solid tumors in humans, we can look with anticipation to studies of polyvalent vaccines for the prevention of carcinoma in high risk groups.

UR - http://www.scopus.com/inward/record.url?scp=0026709733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026709733&partnerID=8YFLogxK

M3 - Article

C2 - 1621207

AN - SCOPUS:0026709733

VL - 175

SP - 89

EP - 96

JO - Journal of the American College of Surgeons

JF - Journal of the American College of Surgeons

SN - 1072-7515

IS - 1

ER -